2018
CD36 gene is associated with intraocular pressure elevation after intravitreal application of anti-VEGF agents in patients with age-related macular degeneration: Implications for the safety of the therapy
MATUŠKOVÁ, Veronika, Vladimír Josef BALCAR, Naim A. KHAN, Ondřej BONCZEK, Laura EWERLINGOVÁ et. al.Základní údaje
Originální název
CD36 gene is associated with intraocular pressure elevation after intravitreal application of anti-VEGF agents in patients with age-related macular degeneration: Implications for the safety of the therapy
Autoři
MATUŠKOVÁ, Veronika (203 Česká republika, domácí), Vladimír Josef BALCAR (36 Austrálie, domácí), Naim A. KHAN (250 Francie), Ondřej BONCZEK (203 Česká republika, domácí), Laura EWERLINGOVÁ (703 Slovensko, domácí), Tomáš ZEMAN (203 Česká republika, domácí), Petr KOLÁŘ (203 Česká republika, domácí), Daniela VYSLOUŽILOVÁ (203 Česká republika, domácí), Eva VLKOVÁ (203 Česká republika, domácí) a Omar ŠERÝ (203 Česká republika, garant, domácí)
Vydání
Ophthalmic Genetics, Philadelphia, Taylor & Francis, 2018, 1381-6810
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30101 Human genetics
Stát vydavatele
Spojené státy
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 1.285
Kód RIV
RIV/00216224:14310/18:00106909
Organizační jednotka
Přírodovědecká fakulta
UT WoS
000428520500002
Klíčová slova anglicky
Glaucoma; polymorphism; receptor; Schlemm´s canal; thrombospondin
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 23. 4. 2024 09:37, Mgr. Michal Petr
Anotace
V originále
Background: The wet form of age-related macular degeneration (AMD) is characterized by pathological vascularization of the outer retinal layers. The condition responds to treatment with antibodies against vascular endothelial growth factor (VEGF), but the patients receiving such anti-VEGF therapy sometimes show undesirable acute short-term increases in the intraocular pressure (IOP). The cause of this adverse effect is unknown, and here, we are testing a hypothesis that it is related to CD36 gene polymorphisms. Materials and Methods: A group of 134 patients with AMD were given three therapeutic doses of anti-VEGF antibody (ranibizumab) at monthly intervals. Their IOP was measured immediately before and 30 min after each injection. Patients’ DNA was analyzed, and the changes in IOP were matched against seven polymorphisms of the CD36 gene. Results: Three polymorphisms were found to be associated with increases in IOP: rs1049673 (p = 0.006), rs3211931 (p = 0.01), and rs1761667 (p = 0.043) at the time of the third injection only. Pronounced elevations (IOP > 25 mmHg) were associated with rs1049673 polymorphism: GC genotype (p < 0.01) and CC genotype (p < 0.05); both increasing the risk 2.6-fold, the presence of C-allele conferring a 1.5-fold greater risk and with rs3211931 polymorphism: AG genotype (p < 0.01) and GG genotype (p < 0.05); increasing the risk 2.6-fold (AG) and 2.7-fold (GG). Conclusions: CD36 receptor may be involved in mediating the effects of VEGF on IOP. The findings will help to identify the patients at risk of acutely elevated IOP following the anti-VEGF therapy.
Návaznosti
NV16-31207A, projekt VaV |
|